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ABSTRACT
Immune thrombocytopenia (ITP) is an entity characterized by a platelet count of less than 100 × 109/L in the absence 
of other causes of thrombocytopenia, such as viral infections, rheumatic diseases, or drugs. Grave’s disease is also an 
autoimmune condition in which thrombocytopenia is often observed. Moreover, in the literature, many reports show a 
marked interference of the thyroid dysfunction (mainly hyperthyroidism) in the control of thrombocytopenia. Although 
this issue still remains debatable, the authors report the case of a young woman with a previous diagnosis of ITP with 
a brilliant initial response to corticotherapy. Some years after this diagnosis, the patient presented thyrotoxicosis due to 
Grave’s disease and the thrombocytopenia relapsed, but this time there was no response to the glucocorticoids. Only after 
the radioiodine I-131 thyroid ablation the control of thrombocytopenia was achieved. The authors call attention to this 
overlap and for testing thyroid function in every patient with an unexpected negative response to corticotherapy.
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CASE REPORT
A 31-year-old Caucasian and previously healthy 
female patient sought medical care complaining 
of petechiae throughout the body associated with 
epistaxis, and bleeding gums after teeth brushing. 
The peripheral blood count revealed thrombocytopenia 
(5 × 109/L) with normal red and white blood cells 
count. The patient was prescribed prednisone with the 
diagnostic hypothesis of immune thrombocytopenia 
(ITP) after a laboratory work-up, comprising antinuclear 
antibodies (ANA), human immunodeficiency virus (HIV) 
antibody, and hepatitis B and C serologies, which 
ruled out secondary causes of thrombocytopenia. 
Therapeutic response was achieved 5 days after 
prednisone prescription.
Four years after the ITP diagnosis, thrombocytopenia 
relapsed and the patient returned to the emergency 
department because of abnormal genital bleeding, 
with a platelet count of 8 × 109/L. After ruling 
out gynecological abnormalities, the patient was, 
once again, hospitalized for corticotherapy. On this 
occasion, the patient presented tachycardia, insomnia, 
tremors, exophtalmy, and a diffuse goiter. Laboratory 
determinations confirmed the diagnosis of Grave’s 
disease by the determination of thyroid stimulating 
hormone (TSH) = 0.02 μIU/mL (reference value [RV]: 
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0.55–4.78 μIU/mL); free T4 = 2.79 ng/dL (RV: 0.89–
1.76 ng/dL); anti-thyroperoxydase (anti-TPO) = 
179 IU/mL (RV: < 34 IU/mL) and anti-thyroglobulin 
(anti-TG) > 500 IU/mL (RV: < 60 IU/mL), and anti-
TSHR Ab = 22.53 IU/L (RV: < 1.75 IU/L). Consequently, 
propylthiouracil was prescribed. During the following 
months the platelet count reached 363 × 109/L. 
The patient did not attend medical follow-up and 
therefore the euthyroidism could not be assured in 
the meantime.
Three years later, the patient returned to the 
emergency department complaining of easy bruising, 
petechiae, epistaxis, and bleeding gums. The platelet 
count was 6 × 109/L, even though she had been 
taking corticosteroids. The TSH determination was 
< 0.01 mcIU/mL (RV: 0.55–4.78 mcIU/mL) and free 
T4 was 6.23 ng/dL (RV: 0.89–1.76 ng/dL). During 
this hospitalization, resistance to the corticotherapy 
was observed since the platelet count remained 
low after more than 4 weeks of 1.5 mg/kg/day 
of prednisone. Since the patient’s adherence to 
the treatment was doubtful and the anti-thyroid 
drugs could be myelotoxic, radioiodine I-131 
thyroid ablation treatment was recommended and 
undertaken after the patient’s agreement. After the 
control of the hyperthyroidism (free T4 = 0.91 ng/dL 
[RV: 0.89–1.76 ng/dL]) the platelet count increased 
markedly in the presence of the tapering dose of the 
corticotherapy (Figure 1).
DISCUSSION
ITP is one of the most common causes of 
thrombocytopenia in otherwise asymptomatic adults. 
ITP is an acquired thrombocytopenia caused by 
autoantibodies against platelet antigens. This entity 
is characterized by persistent thrombocytopenia, 
which is defined by a platelet count of < 100 × 109/L 
(RV: 150–450 × 109/L), with neither abnormalities in the 
white or red blood cells, nor on the peripheral blood 
smear. The diagnosis of ITP is achieved after ruling out 
other potential causes of thrombocytopenia including 
infections by HIV, hepatitis-C virus, hepatitis-B virus, 
drugs, or rheumatologic diseases, such as systemic 
lupus erythematous and antiphospholidid syndrome.1 
The destruction of the platelet–antibody complex 
by the reticuloendothelial system in a rate superior 
to the marrow’s replacement capacity explains the 
physiopathology of thrombocytopenia in ITP.1 In the 
past few years, new evidence suggests that the platelet 
production may also be impaired in patients with ITP.2
Quite frequently, patients with Grave’s disease 
present mild thrombocytopenia, but generally the 
platelet count, in these cases, is > 100 × 109/l.3,4 In 1931, 
Jackson5 first described the association between 
hyperthyroidism and thrombocytopenia. Although 
rare, this association (especially with Grave’s disease 
and Hashimoto’s thyroiditis) has been demonstrated in 
several studies.6,7 When associated, ITP and autoimmune 
thyroid diseases may present simultaneously, although 
the time between the onset of both diseases may vary 
widely from months to years.3,8 Cordiano et al.9 showed 
that autoimmune thrombocytopenia, in the course of 
thyroid disease, is far more prevalent than vice versa. 
In a longitudinal study, 8–14% of patients with ITP 
developed hyperthyroidism10, leading to speculation 
on the physiopathology of this phenomenon. 
Two mechanisms have been proposed to explain this 
association: a) activation of the reticuloendothelial 
system by the thyroid hormones; and b) the presence 
of an autoimmune mechanism able to trigger both 
conditions.11-13 Platelet-associated immunoglobulin G 
and specific platelet antibody were detected in 83% 
and 86% of patients with ITP with and without thyroid 
autoimmune disease, respectively, while anti-thyroid 
antibodies were found in 89% of patients with ITP.9 
An experimental study evaluated the platelet’s life span 
in a group of rats in which hyperthyroidism had been 
Figure 1. Platelet count during treatment with corticoid 
and propylthiouracil, and after thyroid ablation.
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induced by 3,5,3’-triiodothyronine (T3) administration 
and a control group.12 The animals treated with T3 
presented a reduced platelet count due to early platelet 
destruction. When the platelets of animals treated with 
T3 were infused in the animals of the control group, 
the platelet life span returned to normal; however, 
when the platelets of the control group were infused in 
the T3-treated animals the mean platelet survival time 
decreased.14 These results point to the possibility that, 
in Graves disease, thyroid hormones might increase the 
phagocytic activity of the reticuloendothelial system, 
leading to thrombocytopenia.3,12 Genetic predisposition 
for the development of both diseases, associated with 
HLA B8, has also been reported.14,15
However, other studies and case series could not 
show such a parallelism between the clinical courses 
of ITP and thyroid disease, such that, in many cases, no 
improvement in the platelet count was observed after 
the thyroid function control.16,17 The thrombocytopenia 
induced by the reticuloendothelial hyper activation 
is, in general, mild to moderate,12 suggesting that 
this may not be the single mechanism involved in 
the pathogenesis of the marked thrombocytopenia 
observed in ITP.11 Altintas et al.18 found the presence 
of anti-thyroglobulin (anti-TG) in 39% of the patients 
with ITP without evidence of thyroid disease, while this 
finding was positive in only 10% of the control group. 
In this study, many of the patients with ITP and positive 
anti-TG also had positive tests for anti-endomysium, 
and anti-gliadin, which may suggest a substantial 
defect in the immune self-tolerance in this group of 
patients.3,18
Another theory proposes a cross reaction between 
the antibodies anti-thyroid receptors and the platelets 
epitopes, which could explain the association of both 
conditions.17 This hypothesis was strengthened by 
the structural similarity of the platelet membrane 
glycoprotein GPIDα and the TABP (truncated actin 
binding protein), which is the protein to which the 
anti-thyroid antibodies bind.19 This suggests that the 
same anti-thyroid antibodies may react with platelet 
receptors by providing their early destruction.
Nonetheless, the effect of the thyroid disease 
and its treatment on the clinical course of ITP remains 
controversial.3 Differently from the hypothyroidism, 
the majority of case reports of hyperthyroidism and ITP 
show complete remission of the thrombocytopenia or 
a better control with the usual therapeutic modalities.3 
Sugimoto et al.11 report the case of a patient with a 
10-year history of Grave’s disease taking methimazole, 
which showed a parallelism between the platelet 
count and the TSH values. In that report, the ITP 
response could be attributed to the treatment of 
Grave’s disease, since no corticosteroid or other 
immunosuppressor was used.11 An interesting case was 
reported by Jung et al.20, which showed the reversal 
of thrombocytopenia after I-131 thyroid ablation, in a 
patient with the diagnosis of ITP and Grave’s disease. 
In a review of cases on hyperthyroidism associated 
with ITP, it was estimated that 7% of the cases of ITP 
would respond to the treatment of the thyrotoxicosis, 
and that in many cases the thrombocytopenia would 
be resistant to other therapies.3,21
The International Consensus Report on the 
investigation and management of primary immune 
thrombocytopenia, published in 2010,22 classifies the 
thyroid function evaluation and the thyroid antibodies 
research as a test of potential utility in the management 
of ITP, although this recommendation does not take 
into account the basic investigation for patients with 
the suspicion of ITP.
The observation of this case points positively to 
the interference of thyroid function in the response to 
corticotherapy for the control of thrombocytopenia in 
cases of ITP. We suggest, therefore, that the thyroid 
function should always be evaluated in cases presenting 
resistance to the usual ITP treatment protocols.
REFERENCES
1. Neunert C, Lim W, Crowther M, Cohen A, Solberg L 
Jr, Crowther MA. The American Society of Hematology 
2011 evidence-based practice guideline for immune 
thrombocytopenia. Blood. 2011;117(16):4190-207. 
http://dx.doi.org/10.1182/blood-2010-08-302984. 
PMid:21325604.
2. Bromberg ME. Immune thrombocytopenic purpura-
-the changing therapeutic landscape. N Engl J Med. 
2006;355(16):1643-5. http://dx.doi.org/10.1056/
NEJMp068169. PMid:17050888.
3. Cheung E, Liebman HA. Thyroid disease in patients with 
immune thrombocytopenia. Hematol Oncol Clin North 
Am. 2009;23(6):1251-60. http://dx.doi.org/10.1016/j.
hoc.2009.08.003. PMid:19932432.
4. Brent GA. Clinical practice. Graves’ disease. N Engl J Med. 
2008;358(24):2594-605. http://dx.doi.org/10.1056/
NEJMcp0801880. PMid:18550875.
5. Jackson AS. Acute hemorrhagic purpura associated with 
exophthalmic goiter. JAMA. 1931;113:2386-93.
Autopsy and Case Reports 2015; 5(2):45-48
Immune thrombocytopenia and autoimmune thyroid disease: a controversial overlap
48
6. Marshall JS, Weisberger AS, Levy RP, Breckenridge RT. 
Coexistent Idiopathic Thrombocytopenic Purpura and 
Hyperthyroidism. Ann Intern Med. 1967;67(2):411-4. 
http://dx.doi.org/10.7326/0003-4819-67-2-411.
7. Gill H, Hwang YY, Tse E. Primary immune thrombocytopenia 
responding to antithyroid treatment in a patient 
with Graves’ disease. Ann Hematol. 2011;90(2):223-
4. http://dx.doi.org/10.1007/s00277-010-0983-4. 
PMid:20467745.
8. Pavithran K, Sreekumar A, Krishnamohan VE. Idiopathic 
thrombocytopenic purpura associated with Graves’ 
disease--case report. Indian J Med Sci. 1996;50(2):43-6. 
PMid:8979632.
9. Cordiano I, Betterle C, Spadaccino CA, Soini B, Girolami 
A, Fabris F. Autoimmune thrombocytopenia (AITP) 
and thyroid autoimmune disease (TAD): overlapping 
syndromes? Clin Exp Immunol. 1998;113(3):373-8. 
http://dx.doi.org/10.1046/j.1365-2249.1998.00677.x. 
PMid:9737665.
10. Liebman H. Other immune thrombocytopenias. 
Semin Hematol. 2007;44(4, Suppl 5):S24-34. http://
dx.doi.org/10.1053/j.seminhematol.2007.11.004. 
PMid:18096469.
11. Sugimoto K, Sasaki M, Isobe Y, Tamayose K, Hieda M, 
Oshimi K. Improvement of idiopathic thrombocytopenic 
purpura by antithyroid therapy. Eur J Haematol. 
2005;74(1):73-4. http://dx.doi.org/10.1111/j.1600-
0609.2004.00341.x. PMid:15613111.
12. Kurata Y.  NIshioeda Y, Tsubasio T,  KitaninT. 
Thrombocytopenia in Grave’s disease: effect of T3 on 
platelet kinetics. Acta Hematolol. 1980;63:185-90. http://
dx.doi.org/10.1159/000207396.
13. Hofbauer LC, Spitzweg C, Schmauss S, Heufelder AE. Graves 
disease associated with autoimmune thrombocytopenic 
purpura. Arch Intern Med. 1997;157(9):1033-6. http://
dx.doi.org/10.1001/archinte.1997.00440300155015. 
PMid:9140276.
14. Bizzaro N. Familial association of autoimmune 
thrombocytopenia and hyperthyroidism. Am J 
Hematol. 1992;39(4):294-8. http://dx.doi.org/10.1002/
ajh.2830390411. PMid:1348160.
15. Grumet FC, Payne RO, Konishi J, Kriss JP. HL-A 
antigens as markers for disease susceptibility and 
autoimmunity in Graves’ disease. J Clin Endocrinol Metab. 
1974;39(6):1115-9. http://dx.doi.org/10.1210/jcem-39-
6-1115. PMid:4479624.
16. Vergès B, Giroud-Baleydier F, Olsson O, Vaillant G, 
Brun JM, Putelat R. [Association of Basedow’s disease 
and autoimmune thrombopenic purpura. No effect of 
hyperthyroidism on antiplatelet autoimmunity]. Rev Med 
Interne. 1989;10(6):565-9. PMid:2488511.
17. Cohen Aubart F, Jublanc C, Bruckert E. [Graves’ disease 
and autoimmune thrombocytopenic purpura: distinct 
outcomes of the two diseases]. Ann Endocrinol. 
2007;68(1) :55-7.  http:/ /dx.doi.org/10.1016/ j .
ando.2006.12.001. PMid:17292844.
18. Altintas A, Pasa S, Cil T, Bayan K, Gokalp D, Ayyildiz O. 
Thyroid and celiac diseases autoantibodies in patients 
with adult chronic idiopathic thrombocytopenic 
purpura. Platelets. 2008;19(4):252-7. http://dx.doi.
org/10.1080/09537100801894651. PMid:18569860.
19. Leedman PJ, Faulkner-Jones B, Cram DS, et al. Cloning from 
the thyroid of a protein related to actin binding protein 
that is recognized by Graves disease immunoglobulins. 
Proc Natl Acad Sci USA. 1993;90(13):5994-8. http://
dx.doi.org/10.1073/pnas.90.13.5994. PMid:8327473.
20. Jung RS, Parghane RV, Sood A, Bhattacharya A, Mittal BR. 
Primary autoimmune thrombocytopenia and co-existing 
Graves’ disease: Role of radioiodine-131. Indian J Nucl 
Med. 2014;29(3):195-6. http://dx.doi.org/10.4103/0972-
3919.136602. PMid:25210295.
21. Herman J, Resnitzky P, Fink A. Association between 
thyrotoxicosis and thrombocytopenia. A case report and 
review of the literature. Isr J Med Sci. 1978;14(4):469-75. 
PMid:566733.
22. Provan D, Stasi R, Newland AC, et al. International 
consensus report on the investigation and management 
of primary immune thrombocytopenia. Blood. 
2010;115(2):168-86. http://dx.doi.org/10.1182/blood-
2009-06-225565. PMid:19846889.
Conflict of interest: None
Submitted on: February 25, 2015 
Accepted on: April 12, 2015
Correspondence 
Guilherme Nader Marta 
Internal Medicine Department 
Hospital das Clinicas 
Faculdade de Medicina da Universidade de São Paulo 
Av. Dr. Enéas de Carvalho Aguiar, 255 – Pinheiros – São Paulo/SP – Brazil 
CEP: 05403-900 
Phone: +55 (11) 2661-7690 | +55 (11) 2661-6746 
E-mail: gnmarta2@gmail.com
